Cullinan Therapeutics, Inc. (CGEM) - Q1 2026 Filing Summary
Business Context and Reporting Period
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single reporting segment focused on immunology and oncology. As of April 30, 2026, there were 61,458,046 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(49.7) million | $(48.5) million |
| Operating Expenses | $53.7 million | $55.0 million |
| Research & Development (R&D) | $42.1 million | $41.5 million |
| General & Administrative (G&A) | $11.6 million | $13.5 million |
| Interest Income | $4.1 million | $6.6 million |
| Cash & Cash Equivalents | $75.1 million | $76.7 million |
| Total Investments (Short & Long-term) | $315.3 million | $347.8 million |
| Net Cash Used in Operating Activities | $(46.0) million | $(43.2) million |
| Accumulated Deficit | $(637.8) million | $(416.7) million |
Material Changes vs. Prior Period
- Net Loss: Increased by $1.2 million (2.4%) compared to Q1 2025, driven primarily by a decrease in interest income.
- Operating Expenses: Decreased by $1.3 million. R&D expenses increased slightly by $0.7 million due to higher clinical development costs, while G&A expenses decreased by $2.0 million, largely due to a $1.8 million reduction in equity-based compensation.
- Liquidity: Total cash, cash equivalents, and short-term investments decreased from $377.9 million at year-end 2025 to $351.9 million at March 31, 2026. Long-term investments decreased significantly from $58.3 million to $38.5 million.
- Portfolio Changes: The company discontinued development of CLN-619 (gynecological cancers and NSCLC/multiple myeloma) and CLN-617 in late 2025, impacting R&D allocation in Q1 2026.
Guidance, Outlook, and Risks
- Regulatory Milestones: The U.S. FDA accepted a New Drug Application (NDA) for zipalertinib (EGFR ex20ins NSCLC) in April 2026, with a target action date of February 27, 2027. Taiho expects top-line results from the REZILIENT3 Phase 3 trial by the end of 2026.
- Clinical Data: Initial data for CLN-978 (SLE and RA) is expected at the EULAR Congress in June 2026. Data for Velinotamig (SLE) is expected in Q4 2026.
- Liquidity Outlook: Management expects current resources ($393.3 million in cash, equivalents, and investments) to fund operations for at least the next 12 months. No specific revenue guidance was provided as the company has no approved products.
- Financing: In April 2026, the company established an at-the-market equity offering program with TD Cowen to sell up to $200.0 million of common stock.
- Risks: Key risks include the success of clinical trials, regulatory approval timelines, reliance on third-party collaborators (Taiho, Genrix), and the need for additional capital to fund future operations.
Investor Verification Checklist
- Zipalertinib NDA Status: Verify the FDA target action date of February 27, 2027, and potential for approval delays.
- Cash Runway: Confirm the sufficiency of the $393.3 million liquidity position against projected burn rates, especially given the $20 million upfront payment made to Genrix in June 2025.
- Collaboration Terms: Review the cost-sharing and profit-sharing arrangements with Taiho for zipalertinib and the milestone payment structure with Genrix for velinotamig.
- Discontinued Programs: Assess the impact of discontinuing CLN-619 and CLN-617 on the overall pipeline strategy and R&D efficiency.
- Equity Dilution: Monitor the utilization of the new $200 million ATM facility and its potential impact on share count.